Roivant Sciences ROIV Ratios & Valuation
| Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Free cash flow margin | -9,183.5%-3,422pp | -5,761.5%-1,903pp | -3,858.4%-163pp | -3,695.9%-791pp | -2,905.2%-350pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 18.4×-12.3× | 30.7×-3.0× | 33.7×-6.8× | 40.5×+7.1× | 33.5×-4.4× | |
| Quick ratio | 18.4×-12.3× | 30.7×-3.0× | 33.7×-6.8× | 40.5×+7.1× | 33.5×-4.4× | |
| Cash ratio | 5×+4.4× | 0.6×-0.2× | 0.8×-0.1× | 0.8×+0.2× | 0.6×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $6.52+6.5% | $6.13-4.4% | $6.41+0.3% | $6.39-1.1% | $6.46-10.0% | |
| Valuation | ||||||
| Market capitalization | $19.82B+31.4% | $15.09B+46.1% | $10.33B+31.7% | $7.84B+9.0% | $7.2B-16.4% | |
| Enterprise value | $18.51B+22.5% | $15.11B+46.3% | $10.33B+31.6% | $7.85B+8.9% | $7.21B-16.3% | |
| Price / sales | 2,400.1×+1,266× | 1,133.9×+626× | 508.2×+171× | 337.7×+89.9× | 247.8×-34.5× | |
| Price / book | 4.4×+0.8× | 3.5×+1.2× | 2.4×+0.6× | 1.8×+0.3× | 1.5×-0.1× | |
| EV / sales | 2,241.3×+1,106× | 1,135.2×+627× | 508.1×+170× | 337.9×+89.8× | 248×-34.3× | |
| Free cash flow yield | -3.8%+1.3pp | -5.1%+2.5pp | -7.6%+3.4pp | -10.9%+0.8pp | -11.7%-2.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Roivant Sciences's ratios come from?
- Every ratio is computed from Roivant Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
